U.S. health insurers are seeking help from state health officials to foot the bill for a new generation of hepatitis C treatments that could cost the nation $200 billion or more in the next five years. Camilla Graham, assistant professor of medicine at Beth Israel Deaconess Medical Center, is quoted.
